Lotus Neuro Launches to Deliver the Next Generation of Therapies Across the Blood-Brain Barrier
Clinical-stage biotech unveils a modality-agnostic platform and partnership-first model pairing focused ultrasound with medicines for brain cancer, neurodegeneration and other focal neurologic disease
Lotus Neuro, a clinical-stage biotechnology company pairing focused ultrasound with leading therapeutic modalities to treat focal neurologic disease, today announced its public launch. Spun out in December 2025 from Insightec, the global leader in incisionless focused ultrasound, Lotus Neuro is built on a clinically validated platform for precision modulation of the blood-brain barrier (BBB) and is dedicated to solving the delivery problem that has stalled decades of promising neuroscience.
The blood-brain barrier protects the brain, but it also keeps the vast majority of drugs from reaching it in effective concentrations. Many therapies that should work in the brain never get the chance, and a delivery failure is often read as a failure of biology. Lotus Neuro's platform uses the most clinically validated focused ultrasound technology in combination with circulating microbubbles to modulate the barrier across precisely targeted brain volumes, from a few millimeters to a large hemispheric region, in combination with therapeutic administration. The drug itself does not require modification, which makes the approach modality-agnostic: small molecules, antibodies and antibody-drug conjugates, enzymes, gene therapies, oligonucleotides and cell therapies can all be paired with the technology.
